Endocrine News Podcast · Endocrine Society

ENP107: Compounded Obesity Medications

December 3, 2025·12 min·1 clip

Studies found compounded semaglutide formulations can vary by up to 40% from their advertised drug content.

This episode examines the rise of compounded GLP-1 obesity medications like semaglutide, which emerged during drug shortages. Endocrinologist Dr. Michael Weintraub explains the risks of unregulated compounded drugs, including potency inconsistencies and safety concerns, while discussing why cost and access continue to drive their use despite resolved shortages.

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Endocrine News Podcast